Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL‐BFM 95 reinduction treatment
Open Access
- 1 September 2001
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 114 (4) , 794-799
Abstract
Repeated asparaginase treatment has been associated with hypersensitivity reactions against the bacterial macromolecule in a considerable number of patients. Immunological reactions may range from anaphylaxis without impairment of serum asparaginase activity to a very fast decline in enzyme activity without any clinical symptoms. Previous investigations on a limited number of patients have shown high interindividual variability of asparaginase activity time courses and hypersensitivity reactions in about 30% of patients during reinduction treatment. Therefore, monitoring of reinduction treatment was performed prospectively in 76 children with newly diagnosed acute lymphoblastic leukaemia (ALL). According to the ALL‐Berlin–Frankfurt–Münster (BFM) 95 protocol, 10 000 U/m2 body surface area of native Escherichia coli asparaginase (Asparaginase medac) was given on d 8, 11, 15 and 18. In 45/76 children, trough and peak activities were determined with every dose, and also on d 4 and d 11 after the last administration. Data on asparaginase activity were not available from the remaining 31 patients, but information with regard to hypersensitivity reactions only was given. Eighteen out of 76 patients (24%) suffered a clinical hypersensitivity reaction; however, no silent inactivation was observed. Activity in the therapeutic range of greater than 100 U/l for at least 14 d was determined in 43 of the 45 patients who were analysed for enzyme activity.Keywords
This publication has 18 references indexed in Scilit:
- Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemiaBritish Journal of Haematology, 1997
- Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparationsEuropean Journal of Cancer, 1996
- Somatostatin therapy in l‐asparaginase‐induced pancreatitisMedical and Pediatric Oncology, 1994
- Comparative pharmacokinetic studies of three asparaginase preparations.Journal of Clinical Oncology, 1993
- Allergic reactions toErwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions toescherichia coli asparaginaseCancer, 1992
- Anaphylaxis to L-Asparaginase during Treatment for Acute Lymphoblastic Leukemia in Children—Evidence of a Complement-Mediated MechanismPediatric Research, 1985
- Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemiaMedical and Pediatric Oncology, 1977
- Comparison of anaphylactic reactions to asparaginase derived fromEscherichia coli and fromErwinia cultursCancer, 1976
- l-Asparaginase: Inhibition of endogenous RNA polymerase activity regenerating liverArchives of Biochemistry and Biophysics, 1969
- L -Asparaginase: Inhibition of Early Mitosis in Regenerating Rat LiverScience, 1967